泰林生物(300813.SZ):向87名激勵對象授予93.9萬股限制性股票
格隆匯5月9日丨泰林生物(300813.SZ)公佈,公司《2022年限制性股票激勵計劃(草案)》規定的首次授予條件已經成就,根據公司2021年年度股東大會的授權,公司於2022年5月9日召開了第三屆董事會第七次會議和第三屆監事會第七次會議,審議通過《關於向激勵對象首次授予限制性股票的議案》,確定限制性股票的首次授予日為2022年5月9日,以41.66元/股的授予價格向符合授予條件的87名激勵對象授予93.9萬股限制性股票。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.